scPharmaceuticals agrees to be acquired by MannKind for $5.35/share plus CVRs

scPharmaceuticals Inc.

MannKind to purchase all shares via tender offer for $5.35 cash plus one CVR per share worth up to $1.00 in milestone payments.
CVR milestones: up to $0.75 upon FDA approval of SCP-111 by Sep 30, 2026; up to $0.25 upon $120M net sales by Dec 31, 2026.
Principal stockholders (CEO Tucker, OrbiMed) owning ~11.5% of shares agreed to tender and support the deal.
Termination fee of $9.48M payable if scPharma accepts superior proposal; deal expected to close by Dec 23, 2025.

item 1.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.